1. Advances in Gastrointestinal Pharmacotherapy
David C. Metz, Nimish Vakil, Emmet B. Keeffe, Gary R. Lichtenstein 
Clinical Gastroenterology and Hepatology 
Volume 3, Issue 12, Pages (December 2005)
DOI: /S (05)
Copyright © 2005 American Gastroenterological Association Terms and Conditions

2. Figure 1
Mechanism of action of PPIs. Conversion of the drug to a sulphenamide is required. Binding is irreversible.
Clinical Gastroenterology and Hepatology 2005 3, DOI: ( /S (05) )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

3. Figure 2
Postulated mechanism of action of potassium-competitive acid blockers. Note that transformation to a sulphenamide is not required. Concentration in the cell is greater than with conventional PPIs and the binding is ionic and reversible.
Clinical Gastroenterology and Hepatology 2005 3, DOI: ( /S (05) )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

4. Figure 3
Chronic hepatitis C: possible treatment outcomes after therapy. An early virologic response is defined as greater than a 2-log reduction in HCV RNA level at week 12.
Clinical Gastroenterology and Hepatology 2005 3, DOI: ( /S (05) )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

5. Figure 4
IBD mucosal immune response. tff, Trefoil factor family; nf-κB, nuclear factor-κB; apc, antigen presenting cell; tgf, transforming growth factor; cam, cell adhesion molecule.
Clinical Gastroenterology and Hepatology 2005 3, DOI: ( /S (05) )
Copyright © 2005 American Gastroenterological Association Terms and Conditions